GENFIT (XUP.DE) Fundamental Analysis & Valuation

FRA:XUP • FR0004163111

Current stock price

9.36 EUR
+0.86 (+10.12%)
Last:

This XUP.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. XUP.DE Profitability Analysis

1.1 Basic Checks

  • XUP had negative earnings in the past year.
  • XUP had a negative operating cash flow in the past year.
  • In multiple years XUP reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: XUP reported negative operating cash flow in multiple years.
XUP.DE Yearly Net Income VS EBIT VS OCF VS FCFXUP.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

1.2 Ratios

  • XUP's Return On Assets of -17.98% is in line compared to the rest of the industry. XUP outperforms 59.26% of its industry peers.
  • Looking at the Return On Equity, with a value of -74.24%, XUP is in line with its industry, outperforming 54.32% of the companies in the same industry.
Industry RankSector Rank
ROA -17.98%
ROE -74.24%
ROIC N/A
ROA(3y)-8.88%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XUP.DE Yearly ROA, ROE, ROICXUP.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

  • In the last couple of years the Profit Margin of XUP has declined.
  • In the last couple of years the Operating Margin of XUP has declined.
  • With an excellent Gross Margin value of 95.42%, XUP belongs to the best of the industry, outperforming 88.89% of the companies in the same industry.
  • XUP's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for XUP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.42%
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
XUP.DE Yearly Profit, Operating, Gross MarginsXUP.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. XUP.DE Health Analysis

2.1 Basic Checks

  • XUP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for XUP has been increased compared to 1 year ago.
  • The number of shares outstanding for XUP has been increased compared to 5 years ago.
  • The debt/assets ratio for XUP is higher compared to a year ago.
XUP.DE Yearly Shares OutstandingXUP.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
XUP.DE Yearly Total Debt VS Total AssetsXUP.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -0.46, we must say that XUP is in the distress zone and has some risk of bankruptcy.
  • XUP has a Altman-Z score of -0.46. This is comparable to the rest of the industry: XUP outperforms 41.98% of its industry peers.
  • A Debt/Equity ratio of 0.10 indicates that XUP is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.10, XUP is in the better half of the industry, outperforming 64.20% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -0.46
ROIC/WACCN/A
WACC7.66%
XUP.DE Yearly LT Debt VS Equity VS FCFXUP.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • XUP has a Current Ratio of 3.74. This indicates that XUP is financially healthy and has no problem in meeting its short term obligations.
  • XUP's Current ratio of 3.74 is fine compared to the rest of the industry. XUP outperforms 72.84% of its industry peers.
  • XUP has a Quick Ratio of 3.74. This indicates that XUP is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 3.74, XUP is in the better half of the industry, outperforming 77.78% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.74
Quick Ratio 3.74
XUP.DE Yearly Current Assets VS Current LiabilitesXUP.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. XUP.DE Growth Analysis

3.1 Past

  • XUP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -289.19%.
  • XUP shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -70.77% yearly.
  • XUP shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -45.94%.
  • XUP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.61% yearly.
EPS 1Y (TTM)-289.19%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-137.74%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-45.28%

3.2 Future

  • XUP is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -29.44% yearly.
  • XUP is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -2.23% yearly.
EPS Next Y-213.72%
EPS Next 2Y-83.29%
EPS Next 3Y-41.45%
EPS Next 5Y-29.44%
Revenue Next Year-28.5%
Revenue Next 2Y-13.72%
Revenue Next 3Y-2.98%
Revenue Next 5Y-2.23%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
XUP.DE Yearly Revenue VS EstimatesXUP.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M
XUP.DE Yearly EPS VS EstimatesXUP.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. XUP.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for XUP. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 917.65, which means the current valuation is very expensive for XUP.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of XUP indicates a somewhat cheap valuation: XUP is cheaper than 67.90% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 23.28. XUP is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 917.65
XUP.DE Price Earnings VS Forward Price EarningsXUP.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 200 400 600 800

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XUP.DE Per share dataXUP.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

  • XUP's earnings are expected to decrease with -41.45% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-83.29%
EPS Next 3Y-41.45%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. XUP.DE Dividend Analysis

5.1 Amount

  • No dividends for XUP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

XUP.DE Fundamentals: All Metrics, Ratios and Statistics

GENFIT

FRA:XUP (3/11/2026, 7:00:00 PM)

9.36

+0.86 (+10.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-20
Earnings (Next)04-02
Inst Owners11.39%
Inst Owner ChangeN/A
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap468.03M
Revenue(TTM)45.41M
Net Income(TTM)-38.96M
Analysts90
Price Target9.17 (-2.03%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.57%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)11.89%
EPS NY rev (3m)-22.74%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)9%
Revenue NY rev (3m)9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 917.65
P/S 10.31
P/FCF N/A
P/OCF N/A
P/B 8.92
P/tB 220.14
EV/EBITDA N/A
EPS(TTM)-0.7
EYN/A
EPS(NY)0.01
Fwd EY0.11%
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0.91
BVpS1.05
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -17.98%
ROE -74.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.42%
FCFM N/A
ROA(3y)-8.88%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
F-Score2
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 188.34%
Cap/Sales 7.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.74
Quick Ratio 3.74
Altman-Z -0.46
F-Score2
WACC7.66%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-289.19%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-137.74%
EPS Next Y-213.72%
EPS Next 2Y-83.29%
EPS Next 3Y-41.45%
EPS Next 5Y-29.44%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-45.28%
Revenue Next Year-28.5%
Revenue Next 2Y-13.72%
Revenue Next 3Y-2.98%
Revenue Next 5Y-2.23%
EBIT growth 1Y-217.08%
EBIT growth 3Y-53.58%
EBIT growth 5YN/A
EBIT Next Year13.75%
EBIT Next 3Y23.32%
EBIT Next 5YN/A
FCF growth 1Y87.75%
FCF growth 3Y-47.27%
FCF growth 5YN/A
OCF growth 1Y93.86%
OCF growth 3Y-46.21%
OCF growth 5YN/A

GENFIT / XUP.DE Fundamental Analysis FAQ

What is the fundamental rating for XUP stock?

ChartMill assigns a fundamental rating of 2 / 10 to XUP.DE.


What is the valuation status of GENFIT (XUP.DE) stock?

ChartMill assigns a valuation rating of 1 / 10 to GENFIT (XUP.DE). This can be considered as Overvalued.


How profitable is GENFIT (XUP.DE) stock?

GENFIT (XUP.DE) has a profitability rating of 2 / 10.


What is the expected EPS growth for GENFIT (XUP.DE) stock?

The Earnings per Share (EPS) of GENFIT (XUP.DE) is expected to decline by -213.72% in the next year.